ETF涨跌幅排行丨涨幅榜均为创新药相关ETF 科创综指ETF嘉实（589300）收跌14.01%

Market Performance - The market experienced a rebound on July 28, with the ChiNext Index leading the gains, closing up by 0.96% [1] - The Shanghai Composite Index rose by 0.12%, and the Shenzhen Component Index increased by 0.44% [1] Sector Performance - The computing hardware sector saw a significant surge, while innovative drug concept stocks maintained strong performance [1] - Active performance was noted in military and commercial aerospace concept stocks [1] - Conversely, cyclical stocks such as steel and coal experienced collective adjustments [1] ETF Performance - All ETFs that rose were related to innovative drugs, with the East Money Fund's Innovative Drug ETF (159622) leading the market with a 4.1% increase [3] - Other notable ETFs in the innovative drug sector also saw gains, with the Hong Kong Innovative Drug 50 ETF (513780) up by 4.04% and the Hong Kong Innovative Drug ETF (513120) up by 4.01% [3] Policy Updates - On July 24, the National Medical Insurance Administration announced the initiation of the 11th batch of centralized procurement, optimizing specific rules regarding the selection process [2] - The new rules will no longer simply use the lowest bid as a reference point, and companies with the lowest bids must publicly justify their pricing [2] Industry Insights - According to a report by Industrial Securities, the AACR and ASCO meetings this year showcased numerous domestic innovative drugs exceeding expectations, with anticipation for data releases from upcoming industry conferences [4] - There has been ongoing progress in foreign licensing transactions for innovative drugs, with expectations for more high-quality domestic products to explore international opportunities [4]